Trial · NCT01175213
Results by group3,255
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 3,255
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annual Rate of Serious Bacterial Infections | All Participants Treated With IGSC, 10% and rHuPH20 | 0.020 | Estimated infections/year | ||
| Annual Rate of All Infections | All Participants Treated With IGSC, 10% and rHuPH20 | 2.86 | 95% Confidence Interval 2.36 to 3.43 | Number of infections/year | |
| Trough Levels of IgG Maintained During the Study Period in Relation to Dose Frequency | All Participants Treated With rHuPH20 and/or IGSC, 10% | 2-Week Treatment Interval [N=17] | 10.900 | 95% Confidence Interval 9.390 to 13.300 | g/L |
| Trough Levels of IgG Maintained During the Study Period in Relation to Dose Frequency | All Participants Treated With rHuPH20 and/or IGSC, 10% | 3-Week Treatment Interval [N=9] | 12.300 | 95% Confidence Interval 11.500 to 15.300 | g/L |
| Trough Levels of IgG Maintained During the Study Period in Relation to Dose Frequency | All Participants Treated With rHuPH20 and/or IGSC, 10% | 4-Week Treatment Interval [N=47] | 9.760 | 95% Confidence Interval 9.260 to 10.700 | g/L |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | IGSC, 10% - rHuPH20 | Participants aged 2 to <12 years - not related | 0.0000 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | Safety Follow-up - IGSC, 10% or IGIV, 10% Only | Participants aged 2 to <12 years - not related | 0.0000 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | IGSC, 10% - rHuPH20 | Participants aged 2 to <12 years - related | 0.0000 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | Safety Follow-up - IGSC, 10% or IGIV, 10% Only | Participants aged 2 to <12 years - related | 0.0000 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | IGSC, 10% - rHuPH20 | Participants aged 12 to <16 years - not related | 0.0768 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | Safety Follow-up - IGSC, 10% or IGIV, 10% Only | Participants aged 12 to <16 years - not related | 0.0000 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | IGSC, 10% - rHuPH20 | Participants aged 12 to <16 years - related | 0.0000 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | Safety Follow-up - IGSC, 10% or IGIV, 10% Only | Participants aged 12 to <16 years - related | 0.0000 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | IGSC, 10% - rHuPH20 | Participants aged 16 to <65 years - not related | 0.0950 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | Safety Follow-up - IGSC, 10% or IGIV, 10% Only | Participants aged 16 to <65 years - not related | 0.0449 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | IGSC, 10% - rHuPH20 | Participants aged 16 to <65 years - related | 0.0000 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | Safety Follow-up - IGSC, 10% or IGIV, 10% Only | Participants aged 16 to <65 years - related | 0.0000 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | IGSC, 10% - rHuPH20 | Participants aged 65 years and older- not related | 0.5737 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | Safety Follow-up - IGSC, 10% or IGIV, 10% Only | Participants aged 65 years and older- not related | 0.4728 | SAEs/year | |
| The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs | IGSC, 10% - rHuPH20 | Participants aged 65 years and older- related | 0.0000 | SAEs/year |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01175213/results